Australian Streptokinase Trial (ASK)
A multicenter randomized controlled trial will be conducted to test the hypothesis that the intravenous administration of the thrombolytic agent streptokinase within 4 h of the onset of acute ischemic stroke will result in a significant reduction in subsequent morbidity and mortality. Six hundred eligible patients from 20 to 30 centers will be randomized to receive either 1.5 × 106 units of streptokinase or placebo infused over 60 min. Patients will be accrued over a 3-year period and the results analyzed on an intention-to-treat basis. Primary end-points will be death and 3-month disability on Barthel index or, if no significant difference in death rates between treatment and placebo groups exists, the primary end-point will be improvement in Modified Canadian Neurological Score (MCNS) among the living.
KeywordsAcute Ischemic Stroke Steering Committee Barthel Index Proliferative Diabetic Retinopathy Hemorrhagic Transformation
Unable to display preview. Download preview PDF.